BBO-11818 + pembrolizumab + carboplatin + pemetrexed

BBO-11818 + pembrolizumab + carboplatin + pemetrexed is a combination regimen under clinical investigation for the treatment of locally advanced, unresectable or metastatic KRAS-mutant solid tumors, including non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. - **BBO-11818** is a pan-KRAS inhibitor developed to target various KRAS mutants (including KRAS G12D and G12V) in both active and inactive conformations, thereby interrupting KRAS-driven oncogenic signaling pathways and tumor progression[1][4][7]. - **Pembrolizumab** is a monoclonal antibody that blocks the PD-1 (programmed death 1) receptor on T cells, resulting in immune system activation against tumor cells (checkpoint inhibition)[2][4]. - **Carboplatin** is a platinum-based chemotherapy agent that induces DNA cross-linking, leading to apoptotic cell death in rapidly dividing tumor cells[3][5]. - **Pemetrexed** is an antifolate chemotherapy agent inhibiting multiple enzymes involved in folate metabolism and nucleotide synthesis, thus impeding tumor cell replication[3][5]. This combination integrates targeted therapy (BBO-11818), immunotherapy (pembrolizumab), and cytotoxic chemotherapy (carboplatin + pemetrexed) to potentially enhance efficacy in KRAS-mutant cancers with poor prognosis. The regimen is currently being evaluated in a phase 1 clinical trial[4][7].

Other names

Keytruda (pembrolizumab)Alimta (pemetrexed)